Stock Market Reviews

RVTY (Revvity, Inc.) News

Get the latest news, insights, and market updates on RVTY (Revvity, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 3 Healthcare Stocks Walking a Fine Line
  From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 10.8% over the past six months, topping the S&P 500 by 4.1 percentage points.
  Feb 19, 2026 - $RVTY
• Revvity to Present at Upcoming Investor Conferences
  WALTHAM, Mass., February 17, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:
  Feb 17, 2026 - $RVTY
• New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally
  New England Biolabs (NEB ®) will present several scientific posters at this week's Society for Laboratory Automation and Screening (SLAS) meeting in Boston, MA, highlighting collaborations with leading laboratory liquid-handling automation providers, including Beckman Coulter Genomics, Eppendorf, Hamilton Company, Revvity, and SPT Labtech to support customer implementation of NEBNext® reagents for next-generation sequencing (NGS) library preparation.
  Feb 6, 2026 - $RVTY
• 3 Unpopular Stocks We Think Twice About
  When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
  Feb 6, 2026 - $RVTY
• Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
  WALTHAM, Mass., February 05, 2026--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,
  Feb 5, 2026 - $RVTY
• Revvity Q4 Earnings Call Highlights
  Revvity (NYSE:RVTY) executives said the company ended 2025 with results that exceeded internal expectations, helped by better-than-anticipated performance in diagnostics and improving trends in parts of the life sciences portfolio. Management also provided an initial 2026 outlook that assumes recent
  Feb 2, 2026 - $RVTY
• Stocks Fall Pre-Bell as Traders Await Fresh Labor Market Data, Corporate Earnings
  The benchmark US stock measures were trending lower before the opening bell Monday as investors look
  Feb 2, 2026 - $RVTY
• Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates
  RVTY stock climbs after Q4 adjusted EPS of $1.70 top estimates with revenue improving 5.9% to $772.1 million.
  Feb 2, 2026 - $RVTY
• Revvity (RVTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
  While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
  Feb 2, 2026 - $RVTY
• Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates
  Revvity (RVTY) delivered earnings and revenue surprises of +4.29% and +0.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
  Feb 2, 2026 - $RVTY